Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation

被引:197
作者
Marsh, Rebecca A. [1 ]
Vaughn, Gretchen [1 ]
Kim, Mi-Ok [2 ]
Li, Dandan [2 ]
Jodele, Sonata [1 ]
Joshi, Sarita [1 ]
Mehta, Parinda A. [1 ]
Davies, Stella M. [1 ]
Jordan, Michael B. [1 ,3 ]
Bleesing, Jack J. [1 ]
Filipovich, Alexandra H. [1 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Immunol, Cincinnati, OH 45229 USA
关键词
LINKED LYMPHOPROLIFERATIVE DISEASE; BONE-MARROW-TRANSPLANTATION; SINGLE-CENTER REPORT; VERSUS-HOST-DISEASE; CHIMERISM; GVHD;
D O I
10.1182/blood-2010-04-282392
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent experience suggests that reduced-intensity conditioning (RIC) regimens can improve the outcomes of patients with hemophagocytic lymphohistiocytosis (HLH) undergoing allogeneic hematopoietic cell transplantation (HCT). However, studies directly comparing RIC to myeloablative conditioning (MAC) regimens are lacking. Forty patients with HLH underwent allogeneic HCT between 2003-2009 at Cincinnati Children's Hospital. Fourteen patients received MAC consisting of busulfan, cyclophosphamide, and antithymocyte globulin plus or minus etoposide. Twenty-six patients received RIC consisting of fludarabine, melphalan, and alemtuzumab. All patients engrafted. Acute graft-versus-host disease grades II to III occurred in 14% of MAC patients and 8% of RIC patients (P = .3171). Posttransplantation mixed donor/recipient chimerism developed in 18% of MAC patients and 65% of RIC patients (P = .0110). The majority of patients with mixed chimerism received intervention with reduction of immune suppression plus or minus donor lymphocyte infusion or stem cell boost, which stabilized or increased donor contribution to hematopoiesis and prevented relapse of HLH in all but 1 patient. Grade II to III graft-versus-host disease occurred in 5 of 14 RIC patients after donor lymphocyte infusion. The overall estimated 3-year survival after HCT was 43% (confidence interval = +/- 26%) for MAC patients and 92% (confidence interval = +/- 11%) for RIC patients (P = .0001). We conclude that RIC significantly improves the outcome of patients with HLH undergoing allogeneic HCT. (Blood. 2010;116(26):5824-5831)
引用
收藏
页码:5824 / 5831
页数:8
相关论文
共 24 条
[1]   Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis [J].
Baker, K. S. ;
Filipovich, A. H. ;
Gross, T. G. ;
Grossman, W. J. ;
Hale, G. A. ;
Hayashi, R. J. ;
Kamani, N. R. ;
Kurian, S. ;
Kapoor, N. ;
Ringden, O. ;
Eapen, M. .
BONE MARROW TRANSPLANTATION, 2008, 42 (03) :175-180
[2]   Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation [J].
Baker, KS ;
DeLaat, CA ;
Steinbuch, M ;
Gross, TG ;
Shapiro, RS ;
Loechelt, B ;
Harris, R ;
Filipovich, AH .
BLOOD, 1997, 89 (10) :3857-3863
[3]   Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis [J].
Cooper, N ;
Rao, K ;
Gilmour, K ;
Hadad, L ;
Adams, S ;
Cale, C ;
Davies, G ;
Webb, D ;
Veys, P ;
Amrolia, P .
BLOOD, 2006, 107 (03) :1233-1236
[4]   The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis [J].
Cooper, N. ;
Rao, K. ;
Goulden, N. ;
Webb, D. ;
Amrolia, P. ;
Veys, P. .
BONE MARROW TRANSPLANTATION, 2008, 42 (Suppl 2) :S47-S50
[5]   Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells [J].
Cote, Marjorie ;
Menager, Mickael M. ;
Burgess, Agathe ;
Mahlaoui, Nizar ;
Picard, Capucine ;
Schaffner, Catherine ;
Al-Manjomi, Fahad ;
Al-Harbi, Musa ;
Alangari, Abdullah ;
Le Deist, Francoise ;
Gennery, Andrew R. ;
Prince, Nathalie ;
Cariou, Astrid ;
Nitschke, Patrick ;
Blank, Ulrich ;
El-Ghazali, Gehad ;
Menasche, Gael ;
Latour, Sylvain ;
Fischer, Alain ;
de Saint Basile, Genevieve .
JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (12) :3765-3773
[6]   Hematopoietic cell transplantation for Chediak-Higashi syndrome [J].
Eapen, M. ;
DeLaat, C. A. ;
Baker, K. S. ;
Cairo, M. S. ;
Cowan, M. J. ;
Kurtzberg, J. ;
Steward, C. G. ;
Veys, P. A. ;
Filipovich, A. H. .
BONE MARROW TRANSPLANTATION, 2007, 39 (07) :411-415
[7]   Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3) [J].
Feldmann, J ;
Callebaut, I ;
Raposo, G ;
Certain, S ;
Bacq, D ;
Dumont, C ;
Lambert, N ;
Ouachée-Chardin, M ;
Chedeville, G ;
Tamary, H ;
Minard-Colin, V ;
Vilmer, E ;
Blanche, S ;
Le Deist, F ;
Fischer, A ;
Saint Basile, GD .
CELL, 2003, 115 (04) :461-473
[8]   Diagnosis and manifestations of chronic graft-versus-host disease [J].
Filipovich, Alexandra H. .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (02) :251-257
[9]   HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis [J].
Henter, Jan-Inge ;
Horne, AnnaCarin ;
Arico, Maurizio ;
Egeler, R. Maarten ;
Filipovich, Alexandra H. ;
Imashuku, Shinsaku ;
Ladisch, Stephan ;
McClain, Ken ;
Webb, David ;
Winiarski, Jacek ;
Janka, Gritta .
PEDIATRIC BLOOD & CANCER, 2007, 48 (02) :124-131
[10]   Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation [J].
Henter, JI ;
Samuelsson-Horne, A ;
Aricò, M ;
Egeler, RM ;
Elinder, G ;
Filipovich, AH ;
Gadner, H ;
Imashuku, S ;
Komp, D ;
Ladisch, S ;
Webb, D ;
Janka, G .
BLOOD, 2002, 100 (07) :2367-2373